Takeda Pharmaceutical Net Debt Growth & History (TAK)
Takeda Pharmaceutical's net debt was ¥4.29T for fiscal 2026.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | ¥4.29T | −¥416.69B | −8.86% |
| 2025 | 2025-03-31 | ¥4.70T | −¥302.11B | −6.04% |
| 2024 | 2024-03-31 | ¥5.01T | ¥677.43B | +15.65% |
| 2023 | 2023-03-31 | ¥4.33T | ¥367.21B | +9.27% |
| 2022 | 2022-03-31 | ¥3.96T | −¥144.61B | −3.52% |
| 2021 | 2021-03-31 | ¥4.11T | −¥719.59B | −14.91% |
| 2020 | 2020-03-31 | ¥4.83T | −¥223.71B | −4.43% |
| 2019 | 2019-03-31 | ¥5.05T | ¥4.36T | +630.51% |
| 2018 | 2018-03-31 | ¥691.14B | — | — |
Takeda Pharmaceutical quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | ¥4.48T | ¥323.05B | +7.77% |
| Q4 2026 | 2026-03-31 | ¥4.29T | −¥416.69B | −8.86% |
| Q3 2026 | 2025-12-31 | ¥4.20T | — | — |
| Q2 2026 | 2025-09-30 | ¥3.96T | — | — |
| Q1 2026 | 2025-06-30 | ¥4.16T | — | — |
| Q4 2025 | 2025-03-31 | ¥4.70T | −¥302.11B | −6.04% |
| Q4 2024 | 2024-03-31 | ¥5.01T | ¥677.43B | +15.65% |
| Q4 2023 | 2023-03-31 | ¥4.33T | ¥367.21B | +9.27% |
| Q4 2022 | 2022-03-31 | ¥3.96T | −¥144.61B | −3.52% |
| Q4 2021 | 2021-03-31 | ¥4.11T | −¥719.59B | −14.91% |
| Q4 2020 | 2020-03-31 | ¥4.83T | −¥223.71B | −4.43% |
| Q4 2019 | 2019-03-31 | ¥5.05T | — | — |
Takeda Pharmaceutical net debt trends
Over the last five fiscal years, Takeda Pharmaceutical's net debt increased from ¥4.11T to ¥4.29T, a change of ¥181.22B. The latest reported quarter, Q1 2027, shows ¥4.48T.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Takeda Pharmaceutical source filings ↗